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The world has seen numerous pandemics in the course of human history. One of the 
most severe ones in recent history 
was the influenza pandemic of 1918 
that infected a third of the world and 
killed between 20-50 million people.1 
Subsequent influenza outbreaks 
that occurred in 1957 and 1968 
killed 2 million and 1 million people 
respectively.2 The HIV/AIDS pandemic 
that began in 1981 has killed about 32 
million people worldwide.3 The Severe 
Acute Respiratory Syndrome Coronavirus 
(SARS-CoV) spread from 2002 to 2003, 
causing about 813 deaths, while the 
H1N1 influenza spread in 2009 led to 
about 575,000 deaths.4 More recently, 
the Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV), which was first 
identified in Saudi Arabia, has caused 
858 deaths since 2012.5 Currently, the 
world is in the grip of the COVID-19 
pandemic caused by the SARS-CoV-2 
virus. From its beginnings in December 
2019 to mid-September 2020, there are 
over 29 million confirmed COVID-19 
cases from around the world with about 
900,000 reported deaths.6 How do we 
protect ourselves and prevent infection? 
Protection from SARS-
CoV-2 infection
One of the most important methods 
of decreasing the burden of 
infectious diseases around the world 
is immunization. Immunization is a 
process by which we develop protection 
or immunity to the pathogen or 
infectious agent causing a disease 
through the administration of a vaccine. 
Vaccines are administered by injection, 
orally, or nasally via aerosol.
How does a vaccine protect us? It 
triggers antibody production and 
cell-mediated immunity against an 
infectious agent or pathogen inside the 
body. This is achieved by exposing our 
body to a killed or weakened pathogen, 
a toxin it produces, or a component 
(like a surface protein), called antigen, 
that can trigger such a response against 







How do vaccines protect 
us from infection? How 
are they developed? How 
quickly can a vaccine 
against COVID-19 be 
made widely available for 
use? What behavioural 
changes can help prevent 
infection? Do our general 
health and immunity 
impact our risk of 
developing severe disease? 
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adjuvants (like aluminum salts) are used 
to increase the immune response that 
the vaccine triggers. Which of these are 
used in vaccines against viruses? Some 
antiviral vaccines are in the form of 
an inactivated virus. Vaccines against 
polio, rabies, influenza, and Japanese 
encephalitis are examples of such 
vaccines that have led to the eradication 
of disease. Other antiviral vaccines 
can be in the form of live attenuated 
viruses. Examples include the oral polio 
vaccine, as well as vaccines against 
measles, mumps, rubella, yellow fever, 
influenza, and rotavirus. Live attenuated 
viral vaccines have low pathogenic 
ability but retain their ability to induce 
immunity. Yet other vaccines may be in 
the form of a component of the virus 
that confers immunity. For example, 
virus-like particles (empty protein shells 
of viruses) have also been used to make 
vaccines against the human papilloma- 
virus, rotavirus, and influenza virus. 
Newer vaccines, like the recombinant 
hepatitis B vaccine, have the viral gene 
of interest cloned and expressed in yeast 
cells to allow easy production. DNA 
vaccines can be in the form of genes of 
interest, which are delivered by direct 
injection into the individual. Some DNA 
vaccines against respiratory viruses are 
delivered nasally through aerosols, while 
others are delivered in edible forms. 
In contrast, RNA vaccines, delivered in 
lipid nanoparticles, induce antibody 
production by coding for proteins that 
resemble those of the pathogen.
As with any medical intervention, the 
general cycle of vaccine development 
and their routine approval for use 
involve multiple stages (see Fig. 1). The 
first stage, called the exploratory stage, 
is used to identify natural or synthetic 
antigens that may prevent disease. In 
the second stage, called the preclinical 
stage, cell or tissue culture systems and 
animals are used to determine if the 
vaccine candidate produces immunity 
or proves harmful. In the third stage, 
called the clinical development stage, 
institutions that receive approval from 
regulatory bodies conduct three phases 
of clinical trials: 
 z Phase I trials are aimed at 
determining safety of the vaccine in a 
small group of volunteers
 z Phase II trials are aimed at 
determining safety, immunogenicity, 
immunization schedule, and dose size in 
a few hundred individuals, and 
 z Phase III trials where thousands or 
tens of thousands of test subjects are 
vaccinated to continue determining 
the safety and effectiveness of the 
candidate vaccine, perform regulatory 
review and approval, manufacturing, 
and quality control.7
The normal route to vaccine approval 
takes at least two decades. But these 
are not normal times. Over the past few 
months, many vaccine companies have 
stepped up to the task of developing 
an anti-COVID-19 vaccine in a matter 
of months rather than decades. For 
example, Oxford University has tied up 
with the Serum Institute of India and 
identified a vaccine candidate that has 
elicited a protective immune response 
in early trials. Meanwhile, Bharath 
Biotech's indigenously produced vaccine, 
Covaxin, has shown an encouraging 
safety profile in Phase I trials. The 
possibility of using a Controlled 
Human Infection Model (CHIM) is also 
being explored in this context. In this 
Fig. 1. How is a new vaccine developed, approved, and manufactured? 
Credits: Adapted from an image by the U.S. Government Accountability Office from Washington, DC, United States, Wikimedia Commons. URL: https://
en.wikipedia.org/wiki/File:The_vaccine_development_process_typically_takes_10_to_15_years_under_a_traditional_timeline._Multiple_regulatory_pathways,_
such_as_Emergency_Use_Authorization,_can_be_used_to_facilitate_bringing_a_vaccine_for_COVID-19_to_(49948301848).jpg. License: CC-BY.
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model, healthy participants consent to 
being deliberately exposed to a well-
characterized and weakened form of 
a pathogen under highly controlled 
conditions. This can help us gather more 
robust information on pathogenesis, 
potential vaccine candidates, duration 
of immunity post-vaccination, and 
the nature of protection in a healthy 
population.8 The key challenge in vaccine 
development for COVID-19 is to achieve 
speed without compromising on the 
regulatory aspects built into the process 
to ensure safety, efficacy, and quality.
Prevention through 
behavioral change
That the SARS-CoV-2 infection is highly 
transmissible is evident by its current 
spread. This infection spreads through 
respiratory droplets released when 
an infected person coughs, sneezes, 
speaks loudly, or sings. Some of these 
droplets land on physical surfaces. An 
uninfected person catches the infection 
when they come into direct or indirect 
(touching a surface contaminated with 
the virus, and then touching one’s nose 
or mouth) contact with these droplets. 
It is now believed that the infection can 
also spread by inhalation of aerosols 
that remain suspended in the air for a 
few minutes to a few hours. The risk 
of transmission increases in closed 
spaces. For example, a study showed 
the presence of the virus in the air up 
to 4 m away from infected patients in a 
hospital. While this is twice the distance 
recommended for physical distancing 
measures, the researchers involved in 
this study also cautioned that the small 
number of viruses found at this distance 
may not necessarily be infectious.9
Not everyone who is infected shows 
clearly identifiable symptoms of disease 
immediately after being infected. Once 
it enters the body, SARS-CoV-2 can go 
through an incubation period that ranges 
from 1-14 days. It usually lasts 3-7 days, 
but could extend to 24 days in some 
cases. During this presymptomatic stage, 
people continue to shed the virus. Other 
infected people show no symptoms at all, 
but can shed the virus and infect others. 
For example, in a study conducted in 
China, a small sample of asymptomatic 
individuals were found to show lower 
antibody levels and a weaker immune 
response. However, they were able to shed 
the virus over a longer duration of time.10 
Who would we be most likely to transmit 
the infection to? Spread is most likely 
to occur among close contacts (family, 
health care workers) at around 1.8 m 
distance.9 
Simple behavioral changes can help 
prevent infection through: 
 z Direct contact with droplets and 
aerosols: Keeping a physical distance of 
up to 2 m (or 6 feet) from other people in 
public spaces is an important preventive 
measure. This can help protect us from 
close contact with infected people, and 
protect others from the risk of infection 
by direct contact with droplets released 
by us. Covering the mouth and nose with 
a cloth mask in public places is crucial, 
particularly when physical distancing 
is difficult to maintain. However, it’s 
important to keep in mind that a mask is 
not a substitute for physical distancing. 
Other important ways of preventing 
infection include the practice of always 
covering the mouth and nose with a 
tissue when coughing or sneezing. If this 
is not available or possible, the inside 
of the elbow may be used instead. If 
a tissue is used, it must be disposed of 
immediately after use, and our hands 
must be washed well with soap and 
water. This will help prevent spread of 
any viruses on our hands to any surface 
or person one encounters next.
 z Indirect contact with fomites or 
contaminated surfaces: Like other 
coronaviruses, SARS-CoV-2 is an 
enveloped RNA virus. It has been found 
to remain active on metal and plastic 
surfaces for up to three days, and on 
soft surfaces (like carpets and curtains) 
for shorter durations. For example, one 
study showed that the floors, computer 
surfaces, handrails, door knobs, and 
waste bins in Intensive Care Units 
(ICU’s) can be contaminated with the 
virus shed by an infected person. How 
long the virus stays active on these 
surfaces depends on many factors. For 
example, SARS-CoV-2 is sensitive to 
ultraviolet rays and heat, but can resist 
the cold (even temperatures below 
0°C). The phospholipid envelope of the 
virus can be effectively inactivated 
by solvents that dissolve lipids. These 
include ether (75%), ethanol, chlorine-
containing disinfectant, peroxyacetic 
acid, and chloroform (except for 
chlorhexidine).11 Soap can also 
effectively inactivate the lipid layer. 
This is why washing hands often with 
soap and water for at least 20 seconds 
(before touching one’s face, eating, 
preparing food; and after using the 
restroom, coughing, sneezing, blowing 
one’s nose, caring for the sick, and 
handling a face mask) is recommended. 
If soap and water are not available, 
then a hand sanitizer with at least 
60% alcohol must be used.11 Surfaces 
that are frequently touched should 
be cleaned and disinfected daily with 
household disinfectants.12
Some categories of individuals are at 
higher risk for severe COVID-19 illness. 
Risk factors in these categories include 
age (with the highest risk in individuals 
above 85 years) and underlying 
medical conditions (like cancer, chronic 
kidney disease, chronic obstructive 
pulmonary disease, obesity, serious 
heart conditions, and Type 2 diabetes 
mellitus). Other individuals who might 
be at risk for severe COVID-19 include 
those with moderate to severe asthma, 
cerebrovascular diseases, high blood 
pressure, immunocompromised states 
(from transplants, immune deficiencies, 
HIV, steroid use), dementia, pregnancy, 
liver disease, lung fibrosis, smokers, 
and Type 1 diabetes mellitus.13 For 
individuals with these risk factors, the 
best way to prevent COVID-19 is to 
avoid contact with infected individuals. 
This is particularly important till COVID-
19-specific drugs and vaccines become 
widely available. People with mild 
symptoms who are otherwise healthy 
are advised to manage their symptoms 
at home so that hospital facilities are 
available for more severely ill patients.
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Parting thoughts
Maintaining a healthy lifestyle (eating 
a balanced diet, getting adequate sleep, 
being physically active, and refraining 
from smoking) is important in keeping 
the immune system healthy to reduce 
episodes and duration of disease. 
However, some supplements are essential 
to proper functioning of the immune 
system, and have been shown in various 
well-conducted studies to lower the risk 
and/or duration of respiratory infections. 
These include vitamin D, zinc, vitamin C 
and vitamin B complex. Other less 
rigorously studied supplements are 
garlic and curcumin (found in turmeric). 
However, no supplement is currently 
known to actually protect against 
COVID-19 per se.
• Immunization is one of the most important methods of decreasing the burden of infectious 
diseases around the world. 
• Vaccines protect us by triggering antibody production and cell-mediated immunity against an 
infectious agent or pathogen that is subsequently encountered inside the body.
• The general cycle of vaccine development involves three stages — exploratory, preclinical, and 
clinical development. 
• The clinical development stage involves three phases of clinical trials to test the safety, efficacy, 
and quality of the vaccine. 
• Many companies have risen to the challenge of developing a vaccine for COVID-19 through 
processes that combine speed with safety, efficacy, and quality. 
• Infection can be prevented through simple behavioural changes like physical distancing, the 
use of face masks, frequent washing of hands with soap and water, as well as disinfecting 
frequently used surfaces. 
• Maintaining a healthy lifestyle is important in keeping the immune system healthy enough to 
reduce episodes and duration of disease. 
Note: Source of the image used in the background of the article title: https://media.istockphoto.com/photos/clinical-trial-vaccine-covid19-coronavirus-in-vial-
with-syringe-on-picture-id1215846334. Credits: Bill Oxford.
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